Abstract: The present invention relates to the use of SCD4 interacting molecules, especially SCD4 inhibitors, for the preparation of a medicament for the treatment of neurodegenerative diseases, particularly Alzheimer's disease.

Abstract: The invention relates to the use of a LAPTM4A-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurogenerative disease. Hereby the LAPTM4A-interacting molecule is preferably an inhibitor of LAPTM4A and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore the invention concerns a process for identifying a gamma-secretase and/or a beta-secretase modulator, comprising the following steps: a. identifying of a LAPTM4A-interacting molecule by determining whether a given test compound is a LAPTM4A-interacting molecule, b. determining whether the LAPTM4A-interacting molecule of step a) is capable of modulating gamma-secretase and/or beta-secretase activity.

Abstract: The invention relates to the use of a GPR49-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurogenerative disease. Hereby s the GPR49-interacting molecule is preferably an inhibitor of GPR49 and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore the invention concerns a process for identifying a gamma-secretase and/or a beta-secretase modulator, comprising the following steps: a. identifying of a GPR49-interacting molecule by determining whether a given test compound is a GPR49-interacting molecule, b. determining whether the GPR49-interacting molecule of step a) is capable of modulating gamma-secretase and/or beta-secretase activity.

Abstract: The present invention relates to the use of DEGS interacting molecules, especially DEGS inhibitors, for the preparation of a medicament for the treatment of neurodegenerative diseases, particularly Alzheimer's disease.

Abstract: The invention relates to the use of a ATP7A-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurogenerative disease. Hereby the ATP7A-interacting molecule is preferably an inhibitor of ATP7A and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore the invention concerns a process for identifying a gamma-secretase and/or a beta-secretase modulator comprising the following steps: a. identifying of a ATP7A-interacting molecule by determining whether a given test compound is a ATP7A-interacting molecule, b. determining whether the ATP7A-interacting molecule of step a) is capable of modulating gamma-secretase and/or beta-secretase activity.

Abstract: The invention relates to the use of a LAPTM4B-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurogenerative disease. Hereby the LAPTM4B-interacting molecule is preferably an inhibitor of LAPTM4B and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore the invention concerns a process for identifying a gamma-secretase and/or a beta-secretase modulator, comprising the following steps: a. identifying of a LAPTM4B-interacting molecule by determining whether a given test compound is a LAPTM4B-interacting molecule, b. determining whether the LAPTM4B-interacting molecule of step a) is capable of modulating gamma-secretase and/or beta-secretase activity.

Abstract: A feeler device has a feeler element pivoted on a carrier for measurement of relative movements between the element and carrier. The element can be located in alternative end positions from which the relative movements take place. The end position is selected by adjustment of a rotatable ring that has a camming surface acting on springs which provide the biassing action that causes one or other end position to be assumed.